Patents by Inventor Jeffrey Schlom

Jeffrey Schlom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Yeast-brachyury immunotherapeutic compositions
    Patent number: 11944673
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: April 2, 2024
    Assignees: The USA, as represented by the Secretary, Dept. of Health and Human Services, GlobeImmune, Inc.
    Inventors: Claudia Palena, Zhimin Guo, David Apelian, Jeffrey Schlom
  • Yeast-brachyury immunotherapeutic compositions
    Patent number: 11938175
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: March 26, 2024
    Assignees: The USA, as represented by the Secretary, Dept. of Health and Human Services, GlobeImmune, Inc.
    Inventors: Claudia Palena, Zhimin Guo, David Apelian, Jeffrey Schlom
  • HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE
    Publication number: 20230331797
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Application
    Filed: June 29, 2023
    Publication date: October 19, 2023
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • HUMAN IMMUNOGENIC EPITOPES OF HEMO AND HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS)
    Publication number: 20230287067
    Abstract: The invention provides human immunogenic epitopes of HEMO and HHLA2 human endogenous retroviruses (HERVs), which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.
    Type: Application
    Filed: January 21, 2021
    Publication date: September 14, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Jeffrey Schlom, Duane H. Hamilton, Claudia M. Palena, Renee N. Donahue
  • HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
    Patent number: 11732017
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: August 22, 2023
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • Combination Immunotherapy Compositions Against Cancer and Methods
    Publication number: 20230256067
    Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.
    Type: Application
    Filed: January 24, 2023
    Publication date: August 17, 2023
    Inventors: James Hodge, Jeffrey Schlom, Alex Franzusoff
  • Combination immunotherapy compositions against cancer and methods
    Patent number: 11596675
    Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: March 7, 2023
    Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: James Hodge, Jeffrey Schlom, Alex Franzusoff
  • Combination immunotherapy compositions against cancer and methods
    Patent number: 11590216
    Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: February 28, 2023
    Assignees: GlobelImmune, Inc., The USA, as represented by the Secretary, Dept, of Health and Human Services
    Inventors: James Hodge, Jeffrey Schlom, Alex Franzusoff
  • BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USE
    Publication number: 20220313801
    Abstract: Brachyury protein can be used to induce Brachyury-specific CD4+ T cells in vivo and ex vivo. It is also disclosed that Brachyury protein can be used to stimulate the production of both Brachyury-specific CD4+ T cells and Brachyury-specific CD8+ T cells in a subject, such as a subject with cancer. In some embodiments, the methods include the administration of a Brachyury protein. In additional embodiments, the methods include the administration of a nucleic acid encoding the Brachyury protein, such as in a non-pox non-yeast vector. In further embodiments, the methods include the administration of host cells expressing the Brachyury protein.
    Type: Application
    Filed: June 6, 2022
    Publication date: October 6, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Jeffrey Schlom, Claudia M. Palena
  • Brachyury protein, non-poxvirus non-yeast vectors encoding Brachyury protein, and their use
    Patent number: 11357839
    Abstract: Brachyury protein can be used to induce Brachyury-specific CD4+ T cells in vivo and ex vivo. It is also disclosed that Brachyury protein can be used to stimulate the production of both Brachyury-specific CD4+ T cells and Brachyury-specific CD8+ T cells in a subject, such as a subject with cancer. In some embodiments, the methods include the administration of a Brachyury protein. In additional embodiments, the methods include the administration of a nucleic acid encoding the Brachyury protein, such as in a non-pox non-yeast vector. In further embodiments, the method include the administration of host cells expressing the Brachyury protein.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: June 14, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, Claudia M. Palena
  • Development of agonist epitopes of the human papillomavirus
    Patent number: 11311613
    Abstract: The invention provides HPV agonist epitopes, which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of HPV infection and/or cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: April 26, 2022
    Assignee: The United States of Americans represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • BRACHYURY DELETION MUTANTS, NON-YEAST VECTORS ENCODING BRACHYURY DELETION MUTANTS, AND THEIR USE
    Publication number: 20210380652
    Abstract: The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.
    Type: Application
    Filed: June 14, 2021
    Publication date: December 9, 2021
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Jeffrey Schlom, Claudia M. Palena
  • HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
    Patent number: 11155588
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: October 26, 2021
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE
    Publication number: 20210253656
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Application
    Filed: April 26, 2021
    Publication date: August 19, 2021
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • Modified yeast-brachyury immunotherapeutic compositions
    Patent number: 11065313
    Abstract: Disclosed are improved yeast-based immunotherapeutic compositions comprising modified Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: July 20, 2021
    Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Thomas H. King, Zhimin Guo, Jeffrey Schlom, Claudia Palena
  • Yeast-MUC1 immunotherapeutic compositions and uses thereof
    Patent number: 11065318
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 20, 2021
    Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Alex Franzusoff, Zhimin Guo, Jeffrey Schlom, Kwong-Yok Tsang
  • Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use
    Patent number: 11034740
    Abstract: The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: June 15, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, Claudia M. Palena
  • Combination Immunotherapy Compositions Against Cancer and Methods
    Publication number: 20210113677
    Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.
    Type: Application
    Filed: December 22, 2020
    Publication date: April 22, 2021
    Inventors: James Hodge, Jeffrey Schlom, Alex Franzusoff
  • YEAST-BRACHYURY IMMUNOTHERAPEUTIC COMPOSITIONS
    Publication number: 20210106666
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.
    Type: Application
    Filed: December 21, 2020
    Publication date: April 15, 2021
    Inventors: Claudia Palena, Zhimin Guo, David Apelian, Jeffrey Schlom
  • Combination Immunotherapy Compositions Against Cancer and Methods
    Publication number: 20210069308
    Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.
    Type: Application
    Filed: November 18, 2020
    Publication date: March 11, 2021
    Inventors: James Hodge, Jeffrey Schlom, Alex Franzusoff